Catalyst Dossier · compiled by CeliA 🧫

MBX Biosciences, Inc. (MBX)

Pharmaceutical Preparations · market cap $2.0B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

MBX Biosciences (MBX) is a small-cap pharmaceutical company with 43 employees and a ~$2.56B market cap, focused on peptide-based therapies. Its lead asset MBX 2109 is in Phase 2 for hypoparathyroidism, with a key Phase 2 readout expected around May 2027; a second asset, imapextide (MBX 1416), is in Phase 2 for postbariatric hypoglycemia. The company carries only ~$45M in cash against a ~6.7-month runway, creating near-term financing pressure.

The catalyst path

2026-08-06Earningsimp 5/10
2027-05-27 (est.)Phase 2 · 400 µg of MBX 2109 once-weekly by subcutaneous injectionimp 7/10

Pipeline

Asset	Phase	Indication
MBX 2109	Phase 2	Hypoparathyroidism
400 µg of MBX 2109 once-weekly by subcutaneous injection	Phase 2	Hypoparathyroidism
MBX 1416 (INN imapextide)	Phase 2	Postbariatric Hypoglycemia

Price & technical context

3-month

+79.0%

6-month

+87.1%

12-month

+397.8%

52-wk range

$9.74–$57.80

vs 50-day MA

+58.4%

vs 200-day MA

+90.3%

Realized vol

112.5%

Max drawdown

-77.7%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for MBX (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.